Arrowhead Pharmaceuticals

Valuation Analysis

About the Company

Arrowhead Pharmaceuticals en bref

Arrowhead Pharmaceuticals (ARWR) is currently trading at 73,56 € with a market capitalization of 10,4 Md €. The 52-week range spans from 13,04 € to 82,98 €; the current price is 11.4% below the yearly high. Year-over-year revenue growth stands at -86.4%.

💰 Dividende

Arrowhead Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

11 analystes évaluent Arrowhead Pharmaceuticals (ARWR) au consensus : Achat Fort. L'objectif de cours moyen est de 93,93 €, soit un potentiel de +27.69% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 82,56 € à 109,50 €.

Arrowhead Pharmaceuticals : la thèse d'investissement en détail

Arrowhead Pharmaceuticals (ARWR) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 100%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 27.69% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -86.4% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 231.05% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

À surveiller

• The analyst consensus price target implies 27.69% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to market-like volatility, elevated short interest (9.53%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Arrowhead Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.